Navigation Links
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
Date:2/8/2013

r 1000 male to 2.8 per 1000 female children, averaged at 3.2 per 1000 children, which is expected to increase due to reduction of premature death.

In the clinical study investigators employ a variety of methods to assess efficacy: K-ABC: Kaufman Assessment Battery for Children, Gross Motor Function Measure, (GMFM), box and block test, Modified Asworth Scale, MAS, finger tapping test, Brain SPECT and MRI.

Dr. JC Ra, president of RNL BIO Stem Cell Technology Institute, said, "It is our mission to find cures for incurable diseases, such as the terrible pediatric curse of cerebral palsy, through autologous stem cell technology." 

About RNL BIO

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell technologies. RNL has completed one phase I trial for spinal cord injury and one Phase II clinical trial for Osteoarthritis and is near to the completion of Buerger's Disease trial. RNL has been a supporter of UN Global Compact's free program to work with children who suffer from cerebral palsy, as major sponsor of the Bethesda Life Foundation. RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.


'/>"/>
SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
2. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
3. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
6. Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... HILL, N.C. , Feb. 27, 2015 ... over the past decade but one thing hasn,t changed: ... MSLs to build relationships with Key Opinion Leaders. ... recognized as the most valuable type of interaction, field ... limits on their KOL interactions. This is just one ...
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015  Acsis Inc., the market ... solutions, announced today that John DiPalo , Acsis, ... Supply & Demand Chain Executive 2015 Provider Pro ... are leading initiatives to help prepare their companies, and ... business climate. This year,s list of Provider Pros to ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... 28, 2015 Dr. Perry Patel ... area residents, recently announced a special offer for the ... treatment option for new and established patients at his Pismo ... a bright, white smile, Dr. Patel and his staff ... marked down from the regular price of $450. , ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a ... new security reader named Guardian 2. The correct ... new biometric scanner that significantly increases the complexity ... new biometric scanner provides fast and easy access ... narcotics lockers with Vanguard technology tracks ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... Madhya Pradesh Tuesday, taking temperatures to more than 46 degrees Celsius ... claimed six more lives taking the toll to 15. ... hot weather would persist for the next two days. ... Damoh. ,The mercury soared to more than 46 ...
... sexually transmitted disease (STD) has surpassed Neisseria gonorrhea in prevalence ... is becoming a big menace, researchers say . ... identified in the 1980s. It can cause inflammation of the ... inflammation of the cervix and the lining of the uterus ...
... Encouraging children to take to swimming is alright. But there ... chlorinated pools could actually increase a child's risk of developing ... asthmatics could be off the mark, a new study seems ... week that children who swam in indoor chlorinated pools during ...
... a good nights rest, for a new study has found ... smoking and drinking . ,The study, conducted by ... based a questionnaire survey among 1,362 adolescents, with an average ... ,The self-administered questionnaire collected data on sleep ...
... Boffins conducting clinical trials of obesity pill Zimulti found that ... Food and Drug Administration (FDA) said that though the 20-milligram ... over one year when taken with a low-calorie diet, there ... drop-out rate in clinical trials. ,"(Zimulti) was shown ...
... will be convened in Vancouver from June 13 to 16. ... and scientists examining many aspects of hair disease and ... loosing hair can weaken a person emotionally. Hair loss is ... career advancement and emotional well being, adds Shapiro, who is ...
Cached Medicine News:Health News:Exposure to Chlorinated Swimming Pools Could Increase Asthma Risk in Children 2Health News:World Largest Hair Congress Convene in Vancouver 2
...
...
...
The Lineage acetabular system with ceramic liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
Medicine Products: